Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2023 | Highlights from SABCS 2023: novel agents and insights on HER2 dynamics in breast cancer

Kevin M. Kalinsky, MD, MS, from the Winship Cancer Institute in Atlanta, GA, discusses exciting posters presented during the spotlight session at the San Antonio Breast Cancer Symposium (SABCS) 2023. The main focus is on new agents, including two bispecific antibodies and a TROP-2 antibody-drug conjugate (ADC). A real-world analysis, RELIEVE, underscores the importance of HER2 dynamics, revealing potential differences in outcomes for patients with HER2-low primary tumors and metastatic tumors. The discussion emphasizes considerations about toxicities, responses, and the optimal measurement of targets, questioning whether targeted therapies induce bystander effects that render assays less critical. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing, protected by global copyright laws. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.